Astrana Health Inc (ASTH) fair value: what the stock is really worth
As of Sep 23, 2026: fair value of Astrana Health Inc $37.93, price $34.34, upside +10.4%, quality 45 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Astrana Health Inc for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.
How to read this chart
60‑month range $18.16 – $119.45 · fair‑value band $26.55 – $49.30 · the $34.34 price screens below the $37.93 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 24, 2026.
Follow Astrana Health in your weekly email
Every Wednesday you see whether Astrana Health is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Astrana Health, Inc., a healthcare management company, provides medical care services in the United States. The company operates through three segments: Care Partners, Care Delivery, and Care Enablement.
Show more
Astrana Health, Inc., a healthcare management company, provides medical care services in the United States. The company operates through three segments: Care Partners, Care Delivery, and Care Enablement. The company offers care coordination services to patients, families, primary care physicians, specialists, acute care hospitals, alternative sites of inpatient care, physician groups, and health plans. Its physician network includes primary care physicians, specialist physicians and extenders, and hospitalists. The company serves patients primarily covered by private or public insurance, such as Medicare, Medicaid, and health maintenance organization; and non-insured patients. The company was formerly known as Apollo Medical Holdings, Inc. and changed its name to Astrana Health, Inc. in February 2024. Astrana Health, Inc. was founded in 1992 and is headquartered in Alhambra, California.
Stock analysis
Astrana Health Inc (ASTH) currently trades at $34.34, while our model-based Fair Value estimate is $37.93, implying the stock looks roughly 9.5% undervalued today.
Show more
Valuation
Bull case: the DCF Models group reads highest at a median of $43.56 per share, and 7 of the 26 models we run sit above the $34.34 price.
Bear case: the Multiples group reads lowest at $9.27, and 19 of the 26 models stay below the price. Evidence for this calculation is medium.
Scenario range: $26.55 (bear) to $49.30 (bull), the price of $34.34 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 45/100 (below-average quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Astrana Health Inc reported revenue of $3.2B in FY2025 versus $774M in FY2021, a compound +42.4%/yr. Reported net income was $22.5M in FY2025, compounding −24.4%/yr from FY2021.
Key figures
Market cap $2.3B · P/E ratio 56.3 · P/S ratio 0.40 · EPS (TTM) $0.6100 · Dividend yield 0.3% · Net margin 0.7% · Return on equity 5.7% · Return on assets (EBIT) 8.3%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 45 out of 100 (low confidence).
What moves the price
The share trades about 31% below its 52-week high and 89% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 35% fair-value upside, at 10%, ASTH screens richer than that median.
Fair Value models
Bear $26.55Fair Value $37.93Bull $49.30
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 9 months old). Earnings retained since then ($0.4462 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.85/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+56.4%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+40.6%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+53.8%
Start year 2020 (pandemic). Over 10 years: +53.4% a year
Revenue growth 18 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+77.9%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Basis: adjusted.
−16.8%
Earnings growth per share plus dividend.
Earnings per share, growth per year−17.1%
Dividend (yield on the price)0.3%
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.2% → 3%
Growth Forecast
Price in line with expectations
The price assumes less growth than the company has delivered so far and about what analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+10.7%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+11.4%
Yearly sales growth analysts expect, extended to five years.
After inflation (USA: IMF forecast 2.4% a year to 2030, 3.1% from 2016 to 2025) that is about +8.1% a year for the price and +8.8% for the forecasts.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Care Facilities · 257 stocks
Beats the industry median on 3/13 measures
Overall it trails its industry peers.
Valuation
Quality Score45 · Below median
Fair Value upside+10% · Above median
Profitability
Return on equity (TTM)6% · Below median
Return on assets4% · Below median
Net margin (TTM)1% · Below median
Operating margin (TTM)3% · Bottom 25%
Growth and dividend
Revenue growth56% · Top 25%
Dividend yield (TTM)0.3% · Bottom 25%
Balance sheet
Debt / equity1.27× · Highest 25%
Valuation Multiplesvs Medical Care Facilities median · lower = cheaper
P/E (TTM)56.3× · Priciest 25%
P/B2.93× · book value is mostly goodwill ⓘGoodwill and other intangible assets are larger than the equity. The book value mainly reflects prices paid for past acquisitions, so we do not rank this P/B against the peer group.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Astrana Health Inc Fair Value". https://www.fairvalue-calculator.com/stock/ASTH
Frequently asked questions
Is Astrana Health Inc (ASTH) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of $37.93 versus a price of $34.34, about +10% upside (undervalued).
What is the fair value of ASTH?
Our model-based fair value for Astrana Health Inc is $37.93 (as of Sep 24, 2026), built from audited fundamentals. The current price: $34.34.
What is the quality score of ASTH?
Astrana Health Inc has a Quality Score of 45/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Astrana Health Inc (ASTH)?
Our model-based price target is the fair value of $37.93 (as of Sep 24, 2026) from 26 valuation models. Cautious scenario $26.55, optimistic scenario $49.30. It is a calculation from audited fundamentals, not an analyst target.
What is the Astrana Health Inc stock forecast for 2026?
Our models put fair value at $37.93, about +10% upside versus a price of $34.34 (undervalued). Cautious scenario $26.55, optimistic scenario $49.30. The calculation is refreshed regularly with new filings.
What is the revenue of Astrana Health Inc (ASTH)?
Astrana Health Inc reported trailing-twelve-month revenue of about $3.5B (latest available figure, as of Sep 24, 2026).
Does Astrana Health Inc pay a dividend?
Astrana Health Inc currently shows a dividend yield of about 0.34% relative to its recent price (as of Sep 24, 2026).
What growth is priced into Astrana Health Inc (ASTH)?
For today's price to be fair in a discounted-cash-flow model, Astrana Health Inc would have to grow free cash flow by +10.7 % per year for five years (discount rate 9.5 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +53.8 % per year. As of Sep 24, 2026.
What discount rate (WACC) does the fair value of ASTH use?
Our models discount Astrana Health Inc at 9.5 %: a base by market capitalisation (mid), damped by beta 0.89, country premium for USA. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Astrana Health Inc that is +10.7 % per year a year over ten years, using the same discount rate (9.5 %) and the same formula as our fair value.
How much growth has Astrana Health Inc (ASTH) delivered so far?
Over the past 5 years revenue at Astrana Health Inc grew +53.8 % a year. The price currently implies +10.7 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Astrana Health Inc (ASTH) growing?
The median revenue growth in the sector is +4.2 % a year. That is the yardstick for the growth priced into Astrana Health Inc (+10.7 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Astrana Health Inc (ASTH)?
The free-cash-flow yield on the price is 6.16 %: that much free cash flow Astrana Health Inc produces per unit of market value. When it exceeds the discount rate of our models (9.5 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Astrana Health Inc (ASTH)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Astrana Health Inc it is $37.93 per share (as of Sep 24, 2026), against a price of $34.34. It is the blended result of 26 valuation models (cash flow, earnings, asset, dividend).
Is Astrana Health Inc stock overvalued or undervalued in 2026?
As of Sep 24, 2026, ASTH trades below its calculated fair value: price $34.34, fair value $37.93, a gap of about +10% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of ASTH?
No. The price is what the market pays today ($34.34); the fair value is what the company's own numbers justify ($37.93). For Astrana Health Inc the two are $3.59 per share apart. That gap is exactly why we show both numbers side by side.
How much is Astrana Health Inc worth?
The market values Astrana Health Inc at about $2.3B (market capitalisation, as of Sep 24, 2026). Per share that is $34.34; our models calculate a fair value of $37.93 per share.
What do the bullish and bearish scenarios say about ASTH?
Our models span a range for Astrana Health Inc: cautious scenario $26.55, base $37.93, optimistic $49.30 per share (as of Sep 24, 2026, price $34.34). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of ASTH?
Astrana Health Inc trades at a price-to-earnings ratio of 56.3 (as of Sep 24, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of $37.93 is built from several models across several years. Other multiples: P/B 2.9, P/S 0.6, EV/EBITDA 17.8.
How solid is the balance sheet of Astrana Health Inc (ASTH)?
Balance-sheet figures for Astrana Health Inc (as of Sep 24, 2026): return on equity 5.7%, debt of 1.27 per unit of equity. They feed the Quality Score of 45/100, which measures business quality independently of the share price.
How far is ASTH from its 52-week high?
Astrana Health Inc trades at $34.34, about 31% below its 52-week high of $49.81 and 89% above the low of $18.16 (as of Sep 23, 2026). Distance from the high says nothing about value: that is what the fair value of $37.93 is for.
Which stocks are comparable to Astrana Health Inc?
From the same area (Healthcare) we also value HCA Healthcare, Inc, Fresenius SE, Dr. Sulaiman Al Habib Medical Services Group, IHH Healthcare Berhad, an investment holding company,, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Astrana Health Inc stock attractive at the current price?
The data as of Sep 24, 2026: price $34.34, calculated fair value $37.93 (+10%), Quality Score 45/100, from 26 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of ASTH calculated?
We run Astrana Health Inc through 26 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $37.93, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.1 % above its aggregate fair value. Astrana Health Inc currently trades 10 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Astrana Health Inc (ASTH)?
The closing price on Sep 23, 2026 was $34.34. Our model-based fair value is $37.93, about +10% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Astrana Health Inc right now?
A fairly wide model range ($26.55 to $49.30) leaves room in how you read the outcome. The price sits in the lower half of our model range, the side with the larger margin of safety. Read the verdict with care: some models are missing inputs, so the estimate scatters more than usual.
Key figures of Astrana Health Inc
How large is the market capitalisation of Astrana Health Inc (ASTH)?
The market capitalisation of Astrana Health Inc is $2.3B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Astrana Health Inc (ASTH)?
The price-to-sales ratio of Astrana Health Inc is 0.40 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Astrana Health Inc (ASTH)?
Earnings per share at Astrana Health Inc are $0.6100 (price ÷ EPS = P/E 56.3). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Astrana Health Inc (ASTH)?
The dividend yield of Astrana Health Inc is 0.3% (payout 19.4%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Astrana Health Inc (ASTH)?
The net margin of Astrana Health Inc is 0.7% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Astrana Health Inc (ASTH)?
The return on equity (ROE) of Astrana Health Inc is 5.7% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Astrana Health Inc (ASTH)?
On an EBIT basis the return on assets of Astrana Health Inc is 8.3% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Astrana Health Inc (ASTH)?
The operating margin of Astrana Health Inc is 3.0% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Astrana Health Inc (ASTH)?
Revenue at Astrana Health Inc is growing +55.6% versus a year earlier (3y avg +40.6%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Astrana Health Inc (ASTH)?
Earnings per share at Astrana Health Inc are growing +110% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Astrana Health Inc (ASTH) carry?
The net debt of Astrana Health Inc is $649M (fiscal year 2025, ≈ 6.2 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Astrana Health Inc in the live analysis
One click puts Astrana Health Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Some data
Sep 24, 2026